EVOMMUNE INC (EVMN) Stock Fundamental Analysis

NYSE:EVMN • US30054Y1073

29.86 USD
+1.98 (+7.1%)
At close: Feb 25, 2026
29.027 USD
-0.83 (-2.79%)
After Hours: 2/25/2026, 4:55:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, EVMN scores 2 out of 10 in our fundamental rating. EVMN was compared to 521 industry peers in the Biotechnology industry. While EVMN seems to be doing ok healthwise, there are quite some concerns on its profitability. EVMN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year EVMN has reported negative net income.
  • EVMN had a negative operating cash flow in the past year.
EVMN Yearly Net Income VS EBIT VS OCF VS FCFEVMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of EVMN (-71.00%) is worse than 63.34% of its industry peers.
  • EVMN has a Return On Equity of -79.64%. This is comparable to the rest of the industry: EVMN outperforms 52.02% of its industry peers.
Industry RankSector Rank
ROA -71%
ROE -79.64%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVMN Yearly ROA, ROE, ROICEVMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EVMN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVMN Yearly Profit, Operating, Gross MarginsEVMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • EVMN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • EVMN has about the same amout of shares outstanding than it did 1 year ago.
  • EVMN has a worse debt/assets ratio than last year.
EVMN Yearly Shares OutstandingEVMN Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 10M 20M 30M
EVMN Yearly Total Debt VS Total AssetsEVMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 46.62 indicates that EVMN is not in any danger for bankruptcy at the moment.
  • EVMN's Altman-Z score of 46.62 is amongst the best of the industry. EVMN outperforms 95.39% of its industry peers.
  • EVMN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of EVMN (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 46.62
ROIC/WACCN/A
WACC8.64%
EVMN Yearly LT Debt VS Equity VS FCFEVMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 9.40 indicates that EVMN has no problem at all paying its short term obligations.
  • EVMN has a Current ratio of 9.40. This is amongst the best in the industry. EVMN outperforms 80.04% of its industry peers.
  • EVMN has a Quick Ratio of 9.40. This indicates that EVMN is financially healthy and has no problem in meeting its short term obligations.
  • EVMN's Quick ratio of 9.40 is amongst the best of the industry. EVMN outperforms 80.23% of its industry peers.
Industry RankSector Rank
Current Ratio 9.4
Quick Ratio 9.4
EVMN Yearly Current Assets VS Current LiabilitesEVMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • EVMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.59%.
  • EVMN shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.00%.
EPS 1Y (TTM)-100.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.77%
Revenue 1Y (TTM)40%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-57.14%

3.2 Future

  • EVMN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.16% yearly.
  • Based on estimates for the next years, EVMN will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-74.63%
EPS Next 2Y-10.53%
EPS Next 3Y-13.16%
EPS Next 5YN/A
Revenue Next Year89.43%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

EVMN Yearly Revenue VS EstimatesEVMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2M 4M 6M 8M 10M
EVMN Yearly EPS VS EstimatesEVMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EVMN. In the last year negative earnings were reported.
  • Also next year EVMN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVMN Price Earnings VS Forward Price EarningsEVMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVMN Per share dataEVMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

  • A cheap valuation may be justified as EVMN's earnings are expected to decrease with -13.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.53%
EPS Next 3Y-13.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EVMN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EVOMMUNE INC

NYSE:EVMN (2/25/2026, 4:55:23 PM)

After market: 29.027 -0.83 (-2.79%)

29.86

+1.98 (+7.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners33.33%
Inst Owner ChangeN/A
Ins Owners4.59%
Ins Owner Change80.47%
Market Cap941.19M
Revenue(TTM)7.00M
Net Income(TTM)-68.31M
Analysts87.14
Price Target39.95 (33.79%)
Short Float %9.73%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.47%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.75%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 134.46
P/FCF N/A
P/OCF N/A
P/B 10.97
P/tB 10.97
EV/EBITDA N/A
EPS(TTM)-2.27
EYN/A
EPS(NY)-2.77
Fwd EYN/A
FCF(TTM)-3.01
FCFYN/A
OCF(TTM)-3.01
OCFYN/A
SpS0.22
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -71%
ROE -79.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.4
Quick Ratio 9.4
Altman-Z 46.62
F-ScoreN/A
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.77%
EPS Next Y-74.63%
EPS Next 2Y-10.53%
EPS Next 3Y-13.16%
EPS Next 5YN/A
Revenue 1Y (TTM)40%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-57.14%
Revenue Next Year89.43%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-84.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.77%
EBIT Next 3Y-26.67%
EBIT Next 5YN/A
FCF growth 1Y-93.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.18%
OCF growth 3YN/A
OCF growth 5YN/A

EVOMMUNE INC / EVMN FAQ

Can you provide the ChartMill fundamental rating for EVOMMUNE INC?

ChartMill assigns a fundamental rating of 2 / 10 to EVMN.


What is the valuation status of EVOMMUNE INC (EVMN) stock?

ChartMill assigns a valuation rating of 0 / 10 to EVOMMUNE INC (EVMN). This can be considered as Overvalued.


What is the profitability of EVMN stock?

EVOMMUNE INC (EVMN) has a profitability rating of 0 / 10.